Tvardi Therapeutics, Inc. Logo

Tvardi Therapeutics, Inc.

Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.

TVRD | IL

Overview

Corporate Details

ISIN(s):
US1407553072 (+1 more)
LEI:
549300COVOY41P0GZ881
Country:
United States of America
Address:
3 SUGAR CREEK CTR. BLVD., 77478 SUGAR LAND
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies. The company's core technology targets STAT3 (Signal Transducer and Activator of Transcription 3), a key regulatory protein implicated in the progression of various diseases. Tvardi is advancing a pipeline of STAT3 inhibitors to treat conditions with significant unmet medical needs, primarily focusing on fibrosis-driven diseases and diverse cancers.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Tvardi Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Tvardi Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Tvardi Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Genome&Company Logo
Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.
South Korea 314130
Develops molecular diagnostics using DNA methylation biomarkers for early cancer detection.
South Korea 228760
Genomtec S.A. Logo
Develops a mobile platform for rapid, precise genetic diagnostics at the point-of-care.
Poland GMT
GENOTECH CORP. Logo
A biotech firm offering gene synthesis, genome analysis, and biopharmaceutical products globally.
South Korea 066830
Genprex, Inc. Logo
A clinical-stage firm developing non-viral gene therapies for cancer and diabetes.
United States of America GNPX
Gentian Diagnostics ASA Logo
Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.
Norway GENT
GERON CORP Logo
Commercializes an approved, first-in-class telomerase inhibitor for blood cancers.
United States of America GERN
GH Research PLC Logo
Clinical-stage biopharma developing mebufotenin therapies for psychiatric disorders.
United States of America GHRS
GI Innovation Inc. Logo
Develops fusion protein biologics for oncology, allergic, and metabolic diseases.
South Korea 358570
GILEAD SCIENCES, INC. Logo
Develops innovative medicines for life-threatening diseases in virology, oncology & inflammation.
United States of America GILD

Talk to a Data Expert

Have a question? We'll get back to you promptly.